EP2124932A2

EP2124932A2 - Use of compounds of the milbemycin family for the treatment of dermatological disorders in human beings

Info

Publication number: EP2124932A2
Application number: EP07823877A
Authority: EP
Inventors: Alexandre Kaoukhov; Cécile COUSIN
Original assignee: Galderma SA
Current assignee: Galderma SA
Priority date: 2006-09-28
Filing date: 2007-09-27
Publication date: 2009-12-02
Also published as: WO2008037937A3; FR2906467B1; WO2008037937A2; FR2906467A1; US20090264517A1

Abstract

The present invention relates to the use of compounds of the milbemycin family or derivatives thereof for producing a pharmaceutical composition for the treatment of dermatological affections in human beings, in particular rosacea.

Description

Use of compounds of the milbemycin family for the treatment of dermatological disorders in humans

The present invention relates to the use of at least one compound of formula (I) or its derivatives, preferably moxidectin or nemadectins, for the manufacture of a pharmaceutical composition intended for the treatment of dermatological conditions in the skin. man, especially rosacea.

Rosacea is a chronic and progressive joint inflammatory dermatosis related to vascular relaxation. It mainly affects the central part of the face and is characterized by facial redness or hot flushes, facial erythema, papules, pustules, and telangiectasias. In severe cases, particularly in man, a facial elephantiasis may develop which most commonly presents as swelling of the soft tissue of the nose producing bulbous swelling called rhinophyma.

Rosacea usually occurs between the ages of 25 and 70, and is much more common in fair-skinned people. It affects more particularly women, although this affection is generally more severe in the man. Rosacea is chronic and persists for years with periods of exacerbation and remission.

The pathogenesis of rosacea is poorly understood. Many factors can be involved without necessarily inducing this condition. These are for example psychological factors, gastrointestinal disorders, environmental factors (exposure to the sun, temperature, humidity) and emotional (stress), food (alcohol, spices), hormonal, vascular, or even an infection with Helicobacter pillori.

The minor forms of rosacea can be treated by topical treatments, for example metronidazole, azelaic acid, benzoyl peroxide, or retinoic acid. As for the most severe forms of the disease, they respond well to general antibiotherapy with cyclins. However, these treatments have unpleasant side effects for the patient, such as irritation or intolerance phenomena. In addition, because of the multi-factorial aspect of rosacea, there are many therapies against this condition, but we are still looking for an effective and safe treatment for the patient.

Surprisingly, the Applicant has now discovered that the compounds of formula (I) below are suitable for the treatment of dermatological conditions in humans and more particularly suitable for the treatment of rosacea:

Thus, the subject of the present invention is the use of at least one compound of formula (I) or its derivatives:

in which R 1 represents a hydroxyl radical or a radical = N-O-R ', where R' is a hydrogen atom or an alkyl radical having from 1 to 6 carbon atoms,

R2 is a hydrogen atom or an alkyl radical having 1 to 6 carbon atoms,

R3 is an alkyl radical having 1 to 6 carbon atoms, for the preparation of a pharmaceutical composition for the treatment of dermatological conditions in humans, including rosacea.

The present invention is exclusively concerned with the therapeutic treatment of humans; in particular, it does not include the therapeutic treatment of animals.

Alkyl having 1 to 6 carbon atoms means a linear or branched alkyl radical, and preferably methyl, ethyl, propyl, isopropyl, butyl and hexyl radicals.

By derivatives of compounds of formula (I) is meant in particular pharmaceutically acceptable salts, and in particular salts formed with a pharmaceutically acceptable acid or base.

The acids may be selected from benzoic acid, optionally substituted, benzenesulfonic acid, citric acid, maleic acid, tartaric acid, phosphoric acid, salicylic acid and gallic acid. The bases may be chosen from alkali metal and alkaline earth metal salts, such as lithium, calcium, sodium potassium or magnesium salts, or salts of aminated heterocycles such as piperidine or morpholine salts.

Preferably, the compounds of formula (I) are those for which: a. R1 is a methyloxime radical (= NOR 'with R' = methyl), R2 is a hydrogen atom, and R3 is an isopropyl radical. Such a compound is moxidectin (or (10E, 14E, 16E) - (1f, 4S, 5'S, 6f, 6'S, 8f, 13f, 20f, 21f, 24S) -6'- [(1E) - 1,3-dimethylbut-1-enyl] -21,24-dihydroxy-5 ', 11,13,22-tetramethyl- (3,7,19-trioxatetracyclo [15.6.1.1 ⁴⁸ .0 ²⁰²⁴ ] pentacosa-10,14 , 16,22-tetraene) -6-spiro-2'

(tetrahydropyran) -2,4'-dione 4 '- (E) - (O-methyloxime); or b. R 1 is a hydroxyl radical, R 2 is chosen from a hydrogen atom and a methyl radical, and R 3 is chosen from methyl and isopropyl radicals. Such compounds correspond to the nemadectins, ie to the nemadectin α (when R 2 = H and R 3 = isopropyl), the nemadectin β (when R 2 = H and R 3 = methyl), the nemadectin Y (when R 2 = -CH 3 and R 3 = methyl ) and nemadectin δ (when R2 = -CH3 and R3 = isopropyl).

Preferably, the compounds are chosen from moxidectin, nemadectin α, nemadectin β, nemadectin Y and nemadectin δ.

Nemadectin α is a natural product derived from the fermentation of Streptomyces cyanogegriseus subsp. Noncyanogenus. Moxidectin is obtained by chemical modification of the nemadectin α.

Moxidectin and nemadectins belong to the group of milbemycins, family of macrocyclic lactones with endotectocidal activity. The mode of action of milbemycins is comparable to that of avermectins. They act on nerve transmission in invertebrates by potentiating the permeability of nematode membranes and insects against chloride ions via glutamate-chloride channels (in connection with GABA _A and glycine receptors). This causes hyperpolarization of the neuromuscular membrane and causes flaccid paralysis and death of the parasite.

The compounds of formula (I), and in particular moxidectin and nemadectins, can thus be formulated in pharmaceutical compositions for human use. said compositions comprise, in a pharmaceutically acceptable medium, at least one compound of formula (I) or its derivatives, preferably moxidectin and nemadectins. The pharmaceutical compositions according to the invention preferably comprise, in a pharmaceutically acceptable medium, at least one nemadectin chosen from nemadectin α, nemadectin β, nemadectin Y and nemadectin δ, preferably nemadectin α.

By pharmaceutically acceptable medium is meant a medium compatible with the skin, mucous membranes and / or integuments.

The pharmaceutical composition that can be used according to the invention is intended for the treatment of human skin and can be administered topically, parenterally or orally. Preferably, the composition is administered topically.

Orally, the pharmaceutical composition may be in liquid, pasty or solid form, in the form of powders and more particularly in the form of tablets, capsules, dragees, syrups, suspensions, solutions, powders, granules , emulsions, microspheres or nanospheres or lipid or polymeric vesicles allowing controlled release.

Parenterally, the composition may be in the form of solutions or suspensions for infusion or injection.

Topically, the composition may be in liquid, pasty or solid form, and more particularly in the form of ointments, creams, milks, ointments, powders, soaked swabs, syndets, wipes, solutions, gels, sprays, mousses, suspensions, lotions, sticks, shampoos, or washing bases. It may also be in the form of suspensions of microspheres or nanospheres or lipid or polymeric vesicles or polymeric patches and hydrogels allowing controlled release. This composition for topical application may be in anhydrous form, in aqueous form or in the form of an emulsion. In a preferred variant of the invention, the topical pharmaceutical composition according to the invention is in the form of a cream or lotion emulsion, a gel, or a solution.

When the composition according to the invention is in the form of an emulsion, it comprises at least one surfactant. Indeed, the conventional emulsions as described in the prior art are unstable quasi-homogeneous systems of two immiscible liquids, one of which is dispersed in the other in the form of fine droplets (micelles). This dispersion is stabilized thanks to the action of surfactant emulsifiers which modify the structure and the ratio of the forces at the interface, and thus increase the stability of the dispersion by reducing the interfacial tension energy.

The surfactant emulsifiers are amphiphilic compounds which have a hydrophobic part having an affinity for the oil and a hydrophilic part having an affinity for water thus creating a link between the two phases. Ionic or nonionic emulsifiers thus stabilize the oil / water emulsions by adsorbing at the interface and forming lamellar layers of liquid crystals.

The emulsifying power of nonionic surfactants is closely related to the polarity of the molecule. This polarity is defined by the HLB (Hydrophile / Lipophilic Balance). The conventional emulsions are generally stabilized by a mixture of surfactants whose HLB may be quite different but whose proportion in the mixture corresponds to the required HLB of the fatty phase to be emulsified.

Among the surfactants that may be used according to the invention, mention may be made, by way of example, of the glyceryl / PEG100 stearate sold under the name Arlacel 165FL by the company Uniqema or under the name Simulsol 165 by the company SEPPIC, esters of polyoxyethylenated fatty acids such as Arlatone 983 from the company Uniqema or the polyoxyethylenated stearyl alcohol (2) sold under the name Brij72 combined with the polyethylenated stearyl alcohol (21) sold under the name Brij721 by the company Uniqema, sorbitan esters such as sorbitan oleate sold under the name Arlacel 80 by ICI or sold under the name of Crill 4 by Croda, sorbitan sesquioleate sold under the name Arlacel 83 by the company ICI or sold under the name of Montane 83 by the company SEPPIC, or the isostearate of sorbitan; fatty alcohol ethers.

The composition according to the invention advantageously comprises up to 15% by weight suitable surfactant emulsifier, preferably from 2 to 12% by weight and more particularly from 2 to 6% by weight relative to the total weight of the composition.

The composition in the form of an emulsion thus comprises: a) an oily phase comprising fatty substances; b) at least one surfactant emulsifier; c) at least one compound selected from the compounds of formula (I) and their derivatives; d) one or more solvents and / or propenetrants of the active substance (s); e) and water.

The oily phase of the composition according to the invention may comprise, for example, vegetable, mineral, animal or synthetic oils, silicone oils, Guerbet alcohols or other fatty substances and mixtures thereof.

As an example of mineral oil, there may be mentioned for example paraffin oils of different viscosity such as Primol 352, Marcol 82, Marcol 152 sold by Esso.

As vegetable oil, there may be mentioned sweet almond oil, palm oil, soybean oil, sesame oil, sunflower oil.

As animal oil, there may be mentioned lanolin, squalene, fish oil, mink oil.

Synthetic oils that may be mentioned include esters, such as cetearyl isononanoate sold under the name Cetiol SN by the company Cognis France, diisopropyl adipate, for example, the product sold under the name Ceraphyl 230 by the company ISF, palmitate isopropyl as the product sold under the name Crodamol IPP by the company Croda, caprylic capric triglyceride such as Miglyol 812 sold by the company HuIs / Lambert River.

As silicone oil, mention may be made of a dimethicone such as the product sold under the name of Dow Corning 200 fluid, a cyclomethicone such as the product sold under the name Dow Corning 244 fluid by Dow Corning or the product sold under the name Mirasil CM5 by SACI-CFPA.

Other fatty substances that may be mentioned are fatty acids such as stearic acid, fatty alcohols such as stearyl alcohol, cetostearyl alcohol and cetyl alcohol or their derivatives, and waxes such as beeswax or wax. carnauba, candellilla wax, as well as gums, in particular silicone gums.

The ingredients of the oily phase may be chosen in a varied manner by those skilled in the art in order to prepare a composition having the desired properties, for example in consistency or in texture.

Preferably, the oily phase of the composition according to the invention comprises a synthetic oil and / or a silicone oil, as synthetic oil, isopropyl palmitate is preferred as the product sold under the name Crodamol IPP by the company Croda or isopropyl myristate, such as the product sold under the name Crodamol IPM by Croda, as silicone oil, dimethicone is preferred.

The oily phase of the emulsion according to the invention may be present in a content of between 3 and 50% by weight relative to the total weight of the composition and preferably between 6 and 20% by weight.

The composition according to the invention comprises from 0.001 to 10% of compound (s) of formula (I) or its derivatives by weight relative to the total weight of the composition. Preferably, the composition according to the invention contains from 0.1 to 5% of compound (s) of formula (I) or its derivatives by weight relative to the total weight of the composition.

As examples of solvents and / or propenetrating compounds of formula (I) or their derivatives, mention will preferably be made of propylene glycol, alcohols of the ethanol, isopropanol, butanol, N-methyl 2 pyrrolidone or DMSO type. polysorbate 80, phenoxyethanol and mixtures thereof.

The composition of the invention contains from 0.1% to 20% and preferably from 1% to 10% of a solvent and / or propenetrating compounds of formula (I) or their derivatives. The composition of the invention also contains water ranging from 30 to 95% and preferably from 60 to 80% by weight relative to the total weight of the composition. The water used in the composition according to the invention will preferably be purified water.

The composition according to the invention may also be in the form of a gel; it then comprises one or more gelling compounds, ranging from 0.01 to 5% by weight relative to the total weight of the composition. Among the gelling agents that can be used in the composition according to the invention, mention may be made of carboxyvinyl polymers (carbomers) and, by way of non-limiting examples of carbomer, Carbopol 981, Carbopol ETD 2020, Carbopol 980, Carbopol Ultrez 10 NF, Pemulen TR1 sold by the company NOVEON.

Mention may also be made of cellulose derivatives, for example hydroxypropylmethylcellulose, or hydroxyethylcellulose; xanthan gums, aluminum / magnesium silicates such as Veegum K or Veegum Ultra sold by Vanderbilt, guar gums and the like, polyacrylamides such as the polyacrylamide / isoparaffin C13-14 / laureth-7 mixture such as for example sold by SEPPIC under the name Sepigel 305 or the acrylamide mixture, AMPS copolymer dispersion 40% / isohexadecane under the name of Simulgel 600PHA, or the family of modified starches such as Solanace Structure sold by National Starch or their mixtures.

The composition of the invention preferably contains from 0.01% to 5%, and preferably from 0.1 to 3% of gelling agent.

When the composition is in the form of a solution, it comprises, in addition to the compounds of formula (I) or their derivatives, an aqueous or oily solution, and optionally one or more solvents and / or propenetrating actives as described above.

The pharmaceutical composition according to the invention may also contain inert additives or combinations of these additives, such as

- preservatives;

stabilizing agents;

humidity regulating agents; pH regulating agents; osmotic pressure modifying agents;

UV-A and UV-B filters;

- and antioxidants.

Of course, those skilled in the art will take care to choose the optional compound (s) to be added to these compositions in such a way that the advantageous properties intrinsically attached to the present invention are not or not substantially impaired by the envisaged addition.

These additives may be present in the composition of 0.001 to 20% by weight relative to the total weight of the composition.

The invention also relates to the use of the composition according to the invention for the manufacture of a pharmaceutical preparation for treating dermatological conditions.

The use of the compounds of formula (I) or their derivatives as a medicament, and more particularly for the manufacture of a topical pharmaceutical composition for human use according to the invention is particularly intended for the treatment of rosacea, acne vulgaris, seborrheic dermatitis, perioral dermatitis, acneiform eruptions, transient acantholytic dermatitis, and acne miliaris necrotica.

The use of the compounds of formula (I) or their derivatives for the manufacture of a topical pharmaceutical composition for human use according to the invention is more particularly intended for the treatment of rosacea.

For the purpose of illustration and without any limiting character, various formulations of compositions comprising compounds of formula (I) or their derivatives will now be given.

EXAMPLE 1 Composition 1

% by weight compared

Ingredients to the total weight of the composition

EXAMPLE 2 Composition 2

EXAMPLE 3 Composition 3

Claims

1. Use of at least one compound chosen from the compounds of formula (I) and their derivatives:

(I)

in which R 1 represents a hydroxyl radical or a radical = NO-R ', where R' is a hydrogen atom or an alkyl radical having from 1 to 6 carbon atoms, R 2 is a hydrogen atom or an alkyl radical having of 1 to 6 carbon atoms, R3 is an alkyl radical having 1 to 6 carbon atoms, for the preparation of a pharmaceutical composition for the treatment of dermatological conditions in humans.

2. Use according to claim 1, characterized in that the alkyl radical is chosen from methyl, ethyl, propyl, isopropyl, butyl and hexyl radicals.

3. Use according to claim 1 or 2, characterized in that the derivatives of the compounds of formula (I) are the salts of these compounds with a pharmaceutically acceptable acid or base.

4. Use according to one of claims 1 to 3, characterized in that the compound of formula (I) is moxidectin.

5. Use according to one of claims 1 to 3, characterized in that the compound of formula (I) is chosen from nemadectins.

6. Use according to claim 5, characterized in that the compound of formula (I) is selected from nemadectin α, nemadectin β, nemadectin Y and nemadectin δ.

7. Use according to one of claims 1 to 6, characterized in that the composition is in a form suitable for oral application.

8. Use according to one of claims 1 to 6, characterized in that the composition is in a form suitable for topical application.

9. Use according to claim 8, characterized in that the composition is in the form of an emulsion, a gel or a solution.

10. Use according to any one of claims 1 to 9, characterized in that the composition comprises from 0.001% to 10% by weight of compound (s) of formula (I) or its derivatives relative to the total weight of the composition .

1. Use according to any one of claims 1 to 10, characterized in that the dermatological conditions are selected from rosacea, acne vulgaris, seborrheic dermatitis, perioral dermatitis, acneiform eruptions, transient acantholytic dermatitis and acne miliaris necrotica.

12. Use according to one of claims 1 to 11, characterized in that the dermatological condition is rosacea.

13. Use of at least one compound of formula (I) or its derivatives:

O - R2

(I)

in which R 1 is a hydroxyl radical, R 2 is chosen from a hydrogen atom and a methyl radical, and R 3 is chosen from methyl and isopropyl radicals, as a medicament.